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Insulin-like growth factor-I receptor (IGF-IR) is often overexpressed in malignant tumors, and is involved in the establishment and
maintenance of malignant phenotypes. Tyrosine kinase receptor endocytosis is commonly triggered by ligand binding and occurs
via clathrin-coatedvescicles that transfer the receptor to the lysosome system for degradation.Our study aims at the evaluationof the
mechanisms involved in IGF-IR downregulation in neoplastic (Npl) and non-neoplastic (non-Npl) cells. Exposure to insulin-like
growth factor-I (IGF-I) of human lung adenocarcinoma cell lines (A549 and H1299) triggers IGF-IR ubiquitination and
internalization processes that require energy and are preceded by the phosphorylation of receptor tyrosines. Differently from other
plasma membrane substrates of the ubiquitin system, IGF-IR is degraded mostly by the proteasome in these tumor cell lines. The
degradation is inhibited by lactacystin and unaffected by lysosomal inhibitors such as bafilomycin A1 and NH4Cl. IGF-IR is
processed in a similarmanner also in fresh specimens of human lung tumors,while it requires active lysosomal functions in non-Npl
human lung tissues. These results suggest that the degradation routes of ubiquitinated IGF-IR diverge in normal and Npl cells, and
further support the involvement of IGF-IR signaling in cancer. Suchadifferent route for IGF-IR processingmight takeplace sometime
during development, since both proteasome and lysosome pathways are active in fetal lung human fibroblasts, IMR90 cells.
J. Cell. Physiol. 208: 354–362, 2006.  2006 Wiley-Liss, Inc.
Insulin-like growth factor-I (IGF-I) represents one of
the major players in somatic cell growth during
embryogenesis, neurogenesis, post-natal development,
and metabolism in adult mammals (Jones and Clem-
mons, 1995; Werner, 1998; Carro et al., 2002). The
pleiotropic cellular growth and the metabolic responses
are regulated by its binding to the insulin-like growth
factor type I receptor (IGF-IR) (Baserga, 1995; Stewart
and Rotwein, 1996). This is often overexpressed in
malignant tumors (Werner and Le Roith, 1997), and is
likely involved in induction and maintenance of several
human malignancies such as glio- and neuroblastomas,
breast, lung, colon, and prostate carcinomas (Baserga
et al., 1997; Werner and Le Roith, 1997; Ciechanover,
1998; Werner, 1998). IGF-IR is constituted by hetero-
tetrameric a2b2 structure with two extracellular a sub-
units and two transmembrane b sub-units containing
tyrosine kinase domains (Ullrich et al., 1985; Di
Guglielmo et al., 2003). IGF-IR activation results in
the autophosphorylation of multiple tyrosine residues of
the b sub-units cytoplasmatic domain, which generates
docking sites for src homology or phosphotyrosine
binding domain-containing proteins, and leads to the
phosphorylation/activation of several substrates,
including insulin receptor substrate-1 (IRS-1) (Wang
et al., 1993), and -2 (Sun et al., 1995), Shc proteins
(Pronk et al., 1993), and Gab-1 (White and Kahn, 1994).
Most tyrosine kinase growth factor receptors are
internalized after binding to their respective agonists
(Robinson, 1994; Koenig and Edwardson, 1997) via
clathrin-coated vescicles (Pearse and Robinson, 1990).
Direct evidences and homologies with insulin receptor
signaling pathway (Furlanetto, 1988; Carpentier, 1994)
suggest that binding of IGF-I causes the shift of IGF-IR
from the plasma membrane to early endosomes via
clathrin-coated pits. Where, IGF-I/IGF-IR complex
could be dissociated and inactivated by the acidic
environment of late endosomes; ligands and receptors
are sorted and directed to lysosome degradation or
recycled to cell surface (Navab et al., 2001).
Several proteins, such as cell cycle regulators, tumor
suppressors, oncoproteins, transcriptional activators,
membrane and cytosolic endoplasmic reticulum-synthe-
sized proteins, and cell surface receptors are processed
and degraded via an ubiquitin-mediated pathway
(Hicke, 1999; Ciechanover et al., 2000; Stang et al.,
2000). Ubiquitin is conjugated to substrate proteins
through the formation of an isopeptide bond between the
e amino group of lysine residues in target proteins and
its C-terminal glycin. The polyubiquitin chain is formed
by successive addition of other ubiquitin moieties to the
previously conjugated one; this chain constitutes a
signal for recognition and destruction by the proteasome
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(Ciechanover, 1998). A clear example is presented by the
Saccaromyces cerevisiae, where pherormone binding
determines phosphorylation and ubiquitination of Ste2p
and Ste3p cytoplasmic tails; both modifications are
required for rapid receptor internalization (Reneke
et al., 1988; Hicke and Riezman, 1996; Roth and Davies,
1996). This ubiquitin-dependent processing has also
been described in mammalian cells, and is characteristic
for several proteins such as epidermal growth factor
(EGF) and growth hormone (GH) receptors, and other
plasma membrane proteins, that is, epithelial Naþ
channel (Staub et al., 1997; Bonifacino and Weissman,
1998). Ubiquitination may represent a required struc-
tural modification for the initiation of receptor inter-
nalization (Strous et al., 1996). This process was
recently shown for receptor tyrosine kinases (RTKs) in
mammalian cells, where ligand-induced mono- and
multiple-ubiquitinaton of RTKs determine their final
fate, and initiates the receptor translocation from
plasma membrane to lysosomes (Haglund et al., 2003).
In spite of IGF-IR crucial role in physiology and
pathology, its degradation process is not yet known in
great details. In this study, we monitored IGF-IR ligand-
induced ubiquitination, and correlated such post-trans-
lational modification with its degradation. Here, we also
report the differential fate of IGF-IR in neoplastic (Npl)
and non-neoplastic (non-Npl) human lung.
MATERIALS AND METHODS
Reagents
Materials for sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS–PAGE) were from Biorad (Hercules,
CA); lactacystin, antimycin A, bafilomycin A1, protein-A
sepharose (PAS), protein-G sepharose (PGS) were from
Sigma-Aldrich (St. Louis, MO); tissue culture sera and media
were purchased from Euroclone (Figino, Milan, Italy); recom-
binant human IGF-I (rhuIGF-I) was kindly provided by
Peprotech, Inc. (Rocky Hill, NJ) polyclonal antibodies against
the b chain of IGF-IR (C-20) and actin (C-11) were from Santa-
Cruz Biotechnology (Santa Cruz, CA); polyclonal antibody
against ubiquitin-conjugated proteins (UG9510) was from
Biomol (Plymouth, PA); anti P-Tyr antibody (RC20H) was
from BD Biosciences (San Jose, CA); polyclonal antibody
against epidermal growth factor receptor (EGFR) (2232) was
from Cell Signaling Technology (Beverly, MA). Reagents for
enhanced chemiluminescence were from Amersham Bio-
sciences (Uppsala, Sweden). All other reagents were of high
analytical grade and were purchased from Sigma-Aldrich.
Cells and cell cultures
A549 (human epithelial-like lung adenocarcinoma) IMR90
(human normal lung of fetal origin) cell lines were obtained
from the American Type Culture Collection (ATCC; Manassas,
VA) and maintained in accordance with the manufacturer’s
instructions. H1299 (human lung carcinoma, non-small cell
lung cancer (NSCLC)) cell line was kindly provided by P.P. Di
Fiore (Experimental Oncology, European Institute of Oncol-
ogy, 20141 Milan; Department of Medicine, Surgery, and
Dentistry, University of Milan, 20142 Milan) and maintained
as indicated by ATCC’s instructions. All cell lines were
maintained at 378C in a humidified atmosphere (5% CO2:
95% air) and were routinely sub-cultivated by trypsinization to
keep long-phase growth.
Tissues and patients
The study included Npl and non-Npl lung biopsies (paired
samples from the same patient) from eight different patients
affected by NSCLC, obtained from the Pathology Unit of the
San Paolo Hospital, Milan. Informed consent was obtained
from all of the patients. In all tumor specimens the amount of
Npl cells was equal or exceeded 80% of the sample, confirmed
by histological diagnosis.
Ligand-induced IGF-IR degradation in cell lines
Cell lines, physiologically expressing IGF-IR, were sub-
confluently grown and incubated for 16 h in serum-deprived
culture medium. The experiment was performed in a complete
culture medium at 1% fetal bovine serum (FBS). To inhibit
protein synthesis the cells were subsequently incubated with
cycloheximide (CHX, 10 mg/ml) that was maintained during all
of the assays. After 30 min, ligand IGF-IR internalization was
induced incubating for different time periods with human
recombinant IGF-I (rhuIGF-I) at the indicated concentrations.
Proteasome and lysosome inhibitors (lactacystin, 10 mM;
NH4Cl, 10 mM; bafilomycin A1 1 mM; respectively) were added
5 min prior to IGF-I stimulation and were present throughout
the experiment. Cell plates were harvested on ice, the medium
was removed, and the cells were lysed on SDS containing buffer
(2% SDS, 0.1 M NaAcetate, 0.5 mM EDTA) and proteases
inhibitors. Protein concentration was determined using the
Lowry Ciocalteau’s method with BSA as standard (Lowry et al.,
1951). Equal amounts of solubilized protein (50 mg) were
dissolved in Laemmli sample buffer (Biorad), separated by
SDS–PAGE in reducing conditions, and electroblotted onto
nitrocellulose membranes. The blots were blocked in 5% non-
fat milk, 0.05% Tween-20 in TBS pH 7.5 and probed with
specific antibodies.
Ligand-induced IGF-IR degradation in lung biopsies
Non-neoplastic and Npl lung biopsies obtained immediately
after surgical resection were washed in PBS, cut in small
bits, and incubated in medium supplemented with 1%
heat-inactivated FBS, 1 mM glutamine, 0.02 UI/ml penicillin,
0.02 UI/ml streptomycin. Ligand-induced IGF-IR degradation
was performed in presence of rhuIGF-I (50 ng/ml) in the
experimental conditions indicated before. The experiment was
harvested by samples incubation on ice, medium removal, and
washing with ice-cold PBS. Small bits were homogenized as
indicated below. Equal amounts of protein extracts (75 mg)
were loaded on a gel, electroblotted, and IGF-IR b chain
expression was investigated by western blot as described.
Non-Npl and Npl lung tissues’ homogenization
Biopsies were homogenized in isotonic condition (25 mM
Tris-HCl pH 7.4, 250 mM sucrose, 1% Triton X-100, 1% NP-40,
5 mM EDTA, 1mM EGTA, 1mM phenylmethylsulphonylfluor-
ide, 1mM aprotinin, 1mM leupetin, 2 mM Na3VO4, 2 mM NaF)
with ULTRA-TURRAX T25. Homogenates were centrifuged at
2,500g for 20 min at 48C, the supernatants were collected, and
protein concentrations were determined with Lowry Ciocal-
teau’s method with BSA as standard.
IGF-I-stimulated protein tyrosine phosphorylation
To determine IGF-IR b chain tyrosine phosphorylation, sub-
confluently growing cells were incubated for 16 h in serum-
depleted culture medium. IGF-I was added, or not, to the
medium at the indicated concentration and maintained for
different times. The medium was removed and the cells were
washed twice with ice-cold washing buffer (20 mM Tris-HCl pH
7.6, 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 0.1 mM Na3VO4)
and lysed in RIPA buffer with 2 mM Na3Vo4, 2 mM NaF, and
protease inhibitors. IGF-IR was immunoprecipitated and
electroblotted on PVDF membrane as described above. The
phosphorylated IGF-IR was detected by an anti-phosphotyr-
osine antibody.
Immunoprecipitation and detection of
ubiquitination conjugates
Insulin-like growth factor-I receptor was immunopurified
from human lung biopsies (non-Npl and Npl) and from cell
protein extracts under special condition to prevent deubi-
quitination and dephosphorylation (Govers et al., 1997).
Protein extracts (500 mg) were diluted in immunoprecipitation
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-
100, 2 mM EGTA, 2 mM EDTA, 1% deoxycholic acid, 50 mM
NaF, 1 mM Na3VO4, 10 mg/ml aprotinine, 10 mg/ml leupeptine,
5 mM phenylmethylsulphonylfluoride), IGF-IR were immuno-
precipitated using a polyclonal antibody against its b chain at
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48C overnight. Immunocomplexes were purified by adding
PGS for 3 h at 48C and recovered by centrifugation at 8,000g.
Immunocomplexes-PGS were washed twice with high salt
buffer (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.1% Triton X-
100, 0.05% deoxycholic acid) and once with low salt buffer
(10 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 0.05% deoxycholic
acid). After elution in reduced Laemmli buffer at 958C for5 min,
samples were resolved on SDS–PAGE in reducing condition
and transferred to nitrocellulose membranes. Blots were
probed with rabbit polyclonal anti-ubiquitinated proteins,
followed by horseradish peroxidase-conjugated goat anti-
rabbit antibody (Chemicon, Temecula, CA). ECLTM detection
system was used to visualize proteins.
Quantitative evaluation of autoradiograms
and statistical analyses
The autoradiograms were analyzed using the NIH IMAGE
1.61/fat program written by Wayne Rasband and a Macintosh
computer. Results were statistically evaluated by Fisher’s
exact test, P-values <0.05 were considered statistically
significant. All analyses were performed with GraphPad Prism
4.0 software.
RESULTS
IGF-I receptor b chain is a short-lived protein and
its degradation in lung adenocarcinoma
cells requires energy
The stability of IGF-IR and the ATP requirement for
its degradation were evaluated in A549 cells. The
exposure to 50 ng/ml rhuIGF-I in presence of CHX
(10 mg/ml), a protein synthesis blocker, triggered the
degradation of IGF-I receptor b chain that within 120
and 240 min was reduced by 40% and 75%, respectively
(Fig. 1A lanes 1–3). On the other hand, the degradation
of IGF-IR b was impaired and the receptor expression
remained unchanged (Fig. 1A lanes 4–6) when ATP was
depleted by adding antimycin A to the culture medium
(as described by Ciechanover et al., 2000). These data
show that proteolytic processing of IGF-IR b chain
requires the IGF-I-mediated activation of the receptor
and the presence of ATP. The addition of CHX alone (in
absence of IGF-I) does not cause noticeable changes in
IGF-IR b chain expression.
Time course of IGF-IR tyrosine phosphorylation
correlates with its ubiquitination
The time course of IGF-I-induced b chain tyrosine
phosphorylation and ubiquitination was determined by
incubating A549 cells at 378C with rhuIGF-I (50 ng/ml)
for different times. Cell lysates were prepared, and cell
extracts subjected to immunoprecipitation with anti-
IGF-IR b chain antibody. To evaluate IGF-I receptor
phosphorylation, the precipitates were then resolved by
SDS–PAGE and immunoblotted with phosphotyrosine
antibodies. As shown in Figure 1B, the phosphorylation
of IGF-I receptor was rather quick and detectable within
2 min, the maximum extent was achieved in 5 min. The
data quantification is shown in lower part of Figure 1B.
Fig. 1. IGF-IR b chain degradation is ATP-dependent and its
phosphorylation and ubiquitination are induced by IGF-I. A: In
A549 cells degradation of IGF-IR b chain was monitored as described
in ‘‘Materials and Methods.’’ The experiment was carried out adding
rhuIGF-I (50 ng/ml) in absence (lanes 1–3) or presence (lanes 4–6) of
antimycin A (50 mM). Protein synthesis was blocked by adding CHX.
After cell lysis, proteins were separated by SDS–PAGE and IGF-IR b
chain and b-actin, used as internal control of gel loading, were
visualized as described in ‘‘Materials and Methods.’’ IGF-I addition
causes a drastic decrease of IGF-IR b chain (lanes 1–3) that is
prevented by antimycin A mediated ATP depletion (lanes 4–6), no
IGF-IR decrease was observed when IGF-I was omitted (lanes 7–8).
Band intensities were quantified and plotted as a relative percentage
of the signal at time 0. B: Phosphorylation of IGF-IR b chain was
studied incubating A549 cells with rhuIGF-I as described. Following
IGF-IR b chain immunoprecipitation, samples were analyzed on
SDS–PAGE and electro-transferred to PVDF. IGF-IR b chain
phosphorylation was detected by an anti-phosphotyrosine antibody
(lanes 1–5, upper part). Band intensities were quantified, and
plotted as a relative percentage of the signal at 30 min. C: IGF-IR b
chain ubiquitination was determined with a polyclonal antibody as
described in ‘‘Materials and Methods’’ (lanes 1–3, Ub-proteins in the
upper part). All the experiments were repeated three times with
similar results, and data are expressed as the mean of three
independent experimentsSD.
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Recently ubiquitination was proposed as a regulatory
process for RTK endocytic transport from plasma
membrane to lysosomes (Hicke, 1999; Haglund et al.,
2003). In Figure 1C it is shown that the extent of IGF-IR
b chain ubiquitination increased during the exposure to
its specific ligand.
A functional proteasome system is required for
IGF-IR b chain degradation in lung tumor cell lines
It is known that polyubiquitin tagging is suggestive of
degradation via proteasome (Ciechanover, 1998), and
we have just shown that IGF-IR b chain is ubiquitinated
and degraded by means of an ATP-dependent manner
(Fig. 1). Lactacystin, an inhibitor of chymotrypsin- and
trypsin-like proteasomal proteases, and two lysosomal
proteases inhibitors, NH4Cl and bafilomycin A1, were
used for testing IGF-IR proteasomal degradation.
Lung tumor cells were sub-confluently grown, then
incubated for 16 h in serum-deprived culture medium.
The experiment was performed in a complete culture
medium with 1% FCS, and CHX was added and
maintained throughout the assay for inhibiting protein
synthesis. Exposure of A549 cells to rhuIGF-I caused a
marked reduction of IGF-IR b chain that was already
evident at 120 min (Fig. 2A,E). This ligand-induced
degradation was prevented by the addition to the test
medium of the proteasome inhibitor lactacystin
(Fig. 2B,E). The amount of IGF-IR actually increased
Fig. 2. IGF-IR b chain degradation in A549. A–E: After starvation,
A549 cells were incubated in medium supplemented with 1% serum,
and pre-treated for 30 min with CHX (10 mg/ml), which was
maintained during the entire assay. rhuIGF-I (50 ng/ml) was added
and maintained for the indicated time. Cells were lysed, protein
separated by one-dimensional SDS–PAGE and IGF-IR b chain was
visualized by immunoblot as described before. A: The experiment was
carried out in the absence of any protein degradation inhibitor, or (B)
in presence of lactacystin (L, 10 mM), the levels of IGF-IR decreased
in (A) and increased in (B). When the lysosome inhibitors,
(C) bafilomycin A1 (Bafilo-A1, 1 mM), and (D) NH4Cl (10 mM), were
added IGF-IR levels decreased greatly within 120 min. E: Band
intensities were quantified, normalized to b-actin levels, and plotted
as a relative percentage of the signal at time 0. F: Like in the case of
IGF-IR, after cell starvation, EGFR degradation assays were
performed by adding EGF (20 ng/ml) to the medium supplemented
with 1% serum in presence or in absence of lysosome or proteasome
inhibitors. Data are expressed as the mean of three independent
experimentsSD.
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at 240 min, likely due to a progressive reduction of the
inhibitory action by CHX on protein synthesis. In
contrast, the blockade of lysosomal proteases with
bafilomycin A1 (Fig. 2C,E) or NH4Cl (Fig. 2D,E) did
not affect the degradation process. The functional
activity of lysosomal system in lung tumoral cells was
monitored by evaluating ligand-mediated degradation
of EGFR in A549 cells in presence or absence of lysosome
and proteasome inhibitors. The degradation process of
EGFR is impaired by the blockade of the lysosomal
system with NH4Cl, while lactacystin does not influence
the process (Fig. 2F). Thus the lysosomal system is
present and active in lung cancer cells.
Ligand-induced ubiquitination and degradation of
IGF-IR b chain was also investigated in H1299 cells,
another type of lung tumor cell line. The ubiquitination
of IGF-IR b chain was increased by 30-min exposure
to rhuIGF-I (Fig. 3A). While IGF-IR b chain levels
decreased to 40% of control values in 240 min (Fig. 3B,F),
the co-incubation with lactacystin impaired this process
and prevented IGF-IR degradation (Fig. 3C). This
correlates with the increased ubiquitination of IGF-IR
b chain (Fig. 3A lane 3). Conversely, lysosome inhibitors
did not influence the degradation process (Fig. 3D,E).
The quantifications are shown in Figure 3 part F. All
these data suggest that IGF-IR b chain is degraded
mostly by proteasome pathway in lung tumor cell lines.
IGF-IR b chain ligand-induced ubiquitination and
degradation in lung tumor specimens
Experimental and clinical studies have shown that
IGF-IR is overexpressed in different carcinomas such as
prostate, tyroid, colon, lung (Belfiore et al., 1999; Xie
et al., 1999; Samani et al., 2004), and in synovial
sarcoma (All-Ericsson et al., 2002). We evaluated the
expression of IGF-IR b chain in homogenates derived
from non-Npl and Npl lung tissues of eight different
patients. IGF-IR b chain was expressed at higher levels
in specimens of NSCLC compared to non-tumoral
portion. The IGF-IR expression from samples of three
patients is shown in Figure 4A, while the quantification
of its expression for the eight patients, assessed by
densitometric scanning of the band on autoradiographs,
is shown graphically in Figure 4B. The IGF-IR from
Fig. 3. IGF-IR b chain ubiquitination and degradation in H1299.
A: Ubiquitination of IGF-IR b chain was investigated as described in
‘‘Materials and Methods’’ and with the same procedures described in
the legend of Figure 3. IGF-I exposure enhances IGF-IR b chain
ubiquitination (A) and degradation (B–F). The co-administration of
the proteasome inhibitor lactacystin (L, 10 mM) prevents such a loss
(C), while the presence of lysosome inhibitors (D) bafilomycin A1
(Bafilo-A1, 1 mM) and (E) NH4Cl (10 mM), do not modify IGF-I
promoted receptor degradation. F: Quantitative data were plotted as
described before. Data are expressed as the mean of three independent
experimentsSD.
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homogenates of lung human Npl and non-Npl tissues
was immunoprecipitated as described above for the cell
lines. Precipitates were analyzed on SDS–PAGE and
immunoblotted with a polyclonal antibody against
ubiquitin-conjugated proteins. IGF-IR b chain and its
ubiquitination were more abundant in Npl compared to
non-Npl fresh lung tissue samples (Fig. 4C). Couples of
small bits from Npl and non-Npl lung biopsies of the
same patient were incubated with rhuIGF-I (50 ng/ml)
as it was done previously for the cell lines. IGF-IR b
chain phosphorylation increased significantly within
30 min in both Npl and non-Npl samples (Fig. 4D). IGF-
IRb chain ubiquitination occurs also in tissue specimens
and its extent increased within 15 min and remained as
suchat later check innon-Npl tissuespecimens (Fig.4E).
Similar results were observed with Npl specimens (data
not shown).
The ligand-induced IGF-IR b chain degradation in
fresh Npl and non-Npl lung tissue specimens from the
same patient are shown in Figure 5. To inhibit protein
neo-synthesis, small bits of tissue were pre-incubated
for 30 min with CHX, which, thereafter, was maintained
for the entire assay. In Npl lung specimens the addition
of rhuIGF-I (50 ng/ml) for 240 min caused a 40%
reduction of IGF-IR b chain (Fig. 5A lanes 1 and 2).
That was unaffected by the presence of NH4Cl in the
incubation media (Fig. 5A lanes 5 and 6), and totally
inhibited by lactacystin (Fig. 5A lanes 3 and 4). These
data strongly support the conclusions derived from the
experiments above with lung Npl A549 and H1299 cell
lines. In non-Npl lung specimens the results were
reversed. In 240 min of IGF-I exposure there was a
50% receptor loss, which was prevented by NH4Cl, and
unaffected by lactacystin (Fig. 5B).
IGF-IR b chain degradation occurs via lysosome
and proteasome systems in IMR90 cell line
IMR90 cells are normal lung fibroblast of fetal origin
and represent a further control of our study on the IGF-
IR b chain degradation in normal and Npl lung tissues.
Thirty minutes exposure to IGF-I promotes receptor
ubiquitination that is further increased by the co-
incubation with proteasome inhibitor lactacystin
(Fig. 6A). Moreover, the same results were obtained by
the co-incubation with the lysosome inhibitor NH4Cl
(data not shown). IGF-IR b chain degradation was
promoted by co-incubation with IGF-I (150 ng/ml) and
CHX (10 mg/ml), there was a loss of 120 min (Fig. 6B
lanes 1–3). The further addition of either lactacystin or
NH4Cl prevented such a drop (Fig. 6B lanes 4–9).
Quantitative data are shown in part C of the same
figure. The same results were obtained when IMR90
cells were incubated with bafilomycin A1 as lysosome
inhibitor (data not shown).
DISCUSSION
This study shows that b chain of IGF-IR is a substrate
of the ubiquitin-proteasome system in human lung
cancer cells. The blockade of one pathway at a time with
lactacystin, an inhibitory agent specific for proteasome,
or NH4Cl and bafilomycin A1, for lysosomes proteases,
indicates that IGF-IR b chain is degraded via the
proteasome pathway in lung cancer cells grown in vitro
Fig. 4. IGF-IR b chain expression, phosphorylation, and ubiquitina-
tion in non-Npl and NSCLC specimens. A, B: Protein extracts of
paired non-Npl and Npl lung tissue specimens from eight patients
affected of NSCLC (Materials and Methods) were immunoblotted with
polyclonal antibody recognizing IGF-IR b chain. IGF-IR expression is
increased as shown by the example blots of three patients (A), and by
the quantification of the eight couples of samples (B). Quantitative
data were plotted as described and reported as percentage, where the
100% value was attributed to the non-Npl sample. Statistical analyses
were performed with Fisher’s test (P¼0.032). Npl samples are richer
in IGF-IR that are also ubiquitinated more than Non Npl (C) The IGF-
IR tyrosine phosphorylation of both types of tissues increased after
30 min incubation with IGF-I (D) that increased also the receptor
ubiquitination in non-Npl (E) and Npl tissue (not shown). Equal
amount of proteins (500 mg), from bits of Npl and non-Npl
homogenates from lung tissues of the same patient, were immuno-
precipitated with anti-IGF-IR b chain polyclonal antibody as reported
in ‘‘Materials and Methods.’’ Each immunoprecipitated sample was
equally divided for being analyzed with anti-ubiquitin-conjugated
proteins antibody and anti-IGF-IR b chain antibody. The results are
representative of five independent experiments. Fresh small bits
of non-Npl and Npl lung specimens were incubated with rhuIGF-I
(50 ng/ml) for 30 min. Assay was harvested as described in ‘‘Materials
and Methods.’’ IGF-IR b chain was immunopurified from protein
extracts (300 mg). The eluted samples were equally divided and
analyzed (C) for ubiquitination, and (D) for phosphorylation. The
results are representative of two different experiments.
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and in fresh specimens of lung tumor. Conversely, IGF-
IRb chain is degraded via the lysosomal pathway in non-
Npl lung tissue specimens. In addition, we observed that
the process of receptor downregulation is energy
dependent, a fundamental hallmark for protein degra-
dation by means of the ubiquitin-proteasome system
that requires ATP for the conjugation of ubiquitin
moieties and the assembly of the proteasome (Aviel
et al., 2000).
Mono-ubiquitination of endocytic proteins and RTKs
is a critical sorting signal in endocytosis (Di Fiore et al.,
2003; Haglund et al., 2003). The binding of the ligand to
its specific receptor is required for the ubiquitination of
several cell receptors such as T-cell receptor x chain
(Hou et al., 1994), EGFR (Stang et al., 2000), platelet-
derived growth factor receptor (Mori et al., 1993), and
GH receptor (Strous et al., 1997). A quick autopho-
sphorylation of IGF-IR b chain is observed after
incubation with the specific ligand (Ebina et al., 1985;
Ullrich et al., 1985). In our experimental conditions,
IGF-IR b chain autophosphorylation is followed by
ubiquitination. Such type of sequential process is an
essential step for the activation of ubiquitin-proteasome
pathway in the case of several other substrates including
IkBa, G1 cyclins, mammalian CDK inhibitor p27KIP1, and
b catenin (Kornitzer and Ciechanover, 2000). Here we
report that IGF-I-dependent phosphorylation of IGF-IR
b chain and its consequent ubiquitination occur both in
cell lines and in ex vivo bits of non-Npl and Npl lung
tissues. This is consistent with previous observations in
melanoma cells, where IGF-IR downregulation was
related to p53 suppression that controls its Mdm2-
dependent ubiquitination and degradation (Girnita
et al., 2003). Moreover, our observations that ubiquiti-
nation of IGF-IR takes place in both Npl and non-Npl
specimens suggest that this post-translational modifi-
cation represents a necessary step for the degradation of
this receptor independently by the final mechanism
employed by the cells. The receptor downregulation in
Fig. 5. Different fate of IGF-IR b chain degradation in human Npl
and non-Npl lung specimens. A: IGF-IR b chain degradation was
studied in lung tumor specimen, and (B) in non-Npl lung specimen.
The results are representative of two independent experiments. As
internal control of gel loading, membranes were decorated with anti-b-
actin antibody. The experimental procedures are similar to those of
Figures 2 and 3. IGF-I exposure in presence of CHX causes a marked
drop of IGF-IR b chain that is prevented by lactacystin (L) and
unaffected by NH4Cl in Npl tissue (A). Conversely, the degradation is
unaffected by lactacystin and blocked by NH4Cl in non-Npl tissue (B).
Fig. 6. IGF-IR b chain ubiquitination and degradation in IMR90
cells. A: Ubiquitination of IGF-IR b chain was investigated as
described in ‘‘Materials and Methods.’’ Briefly, cells were incubated
with rhuIGF-I (150 ng/ml) for 30 min, and to inhibit proteasome
degradation lactacystin (L, 10 mM) was added to the medium (lane 3),
IGF-I exposure increases IGF-IR ubiquitination and this is further
increased by lactacystin. B: Ligand-induced IGF-IR b chain degrada-
tion was investigated as described above. Both lactacystin (L, 10 mM)
and NH4Cl (10 mM) prevented the IGF-IR b chain drop. C: Band
intensities were quantified by analysis of the imaging data, normal-
ized to b-actin levels and plotted as a relative percentage of the signal
at time 0. Data are expressed as the mean of three independent
experimentsSD.
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Npl lung cell lines and in fresh Npl tissue specimens was
sensitive to blockade of proteasomal activity, which
determined a stabilization of IGF-IR b chain. While, a
clear degradation of the protein was observed when the
lysosomal activity was inhibited. Moreover, in tumor
cells, the inhibition of the proteasome was accompanied
by accumulation of ubiquitinated IGF-IR b chain. These
evidences clearly indicate that, in lung cancer, the b
chain of IGF-IR is solely degraded by means of the
proteasome system with no switch to the other system
when the proteasome is inhibited. Conversely, the
degradation assay performed in non-Npl lung tissue
specimens showed that ligand-induced receptor b chain
degradation occurs by means of active lysosomal func-
tions. Our present observation that lysosomal inhibitors
do not affect receptor degradation in lung tumor cells
does not exclude the possibility that lysosomal proteo-
lysis may contribute to the degradation of partially
digested IGF-IR, as it was previously suggested for
PDGF-b receptor (Mori et al., 1993). We have, in fact,
monitored the fate of full-length IGF-IR b chain, while
the partially cleaved b chain molecules, due to their
unpredictable changes in molecular size and immuno-
logical reactivity, could not be detected accurately. As
shown in Figure 2F, EGFR is degraded by the lysosomal
system in A549 cells, thus the switch to the proteosomal
degradation pathway is not a general phenomenon in
lung cancer cells, and may represent a peculiarity of
IGF-IR.
Differently from adult cells, human normal lung cells
of fetal origin (IMR90) employ both proteasome and
lysosomal pathways for IGF-IR downregulation. Such
co-existence of both degradation pathways for IGF-IR
was also observed in P6 mouse embryo fibroblasts
transfected with adaptor protein Grb10 and overexpres-
sing IGF-IR (Vecchione et al., 2003). In this study we
observed that undifferentiated IMR90 cells employ a
degradation mechanism in which proteasome and
lysosome cooperate for the degradation of IGF-IR since
the inhibition of one is sufficient to cause receptor
accumulation. Although lactacystin appears more effec-
tive suggesting a major role for the proteasome. The lack
of such dual interdependence in adult cells suggest that
during cell development and differentiation, this dual
route of degradation is driven towards a single mechan-
ism with the prevalence of the lysosomal pathway in
normal healthy cells. Conversely, the progenitor cancer
cells might have reactivated the originally suppressed
ubiquitin-proteasome pathway with an hypothetical
consequent inactivation of the lysosomal route. Rec-
ently, it has been proposed that the protein machinery
that utilizes ubiquitination for ensuring proper endocy-
tosis and degradation of RTKs may regulate the choice of
one way rather than the other (Bache et al., 2004). The
link between these activation and inactivation processes
is still unclear, and might be related to events involved
in tumor initiation and development. This is the case of
human hematopoietic malignancies where proteins,
such as Eps15, endophilin-2, rabaptin-5, are involved
in a faulty organization of clathrin-coated vesicles and
endosomal fusion due to their abnormal structure
caused by the rearrangement of their genes with
oncogenic loci. This subversion might be the basis of
the initiating steps in Npl development (reviewed in
Bache et al., 2004; Polo et al., 2004).
The circulating levels of IGF-I influence many IGF-
IR-positive cancers, thus tumor behavior might be
regulated by IGF-I secreted in autocrine, paracrine,
and endocrine manners (Pollak et al., 2004). A recent
meta-analysis (Renehan et al., 2004) of all published
studies on the association between IGF-I and tumor risk
described an increment in cancer risk in prostate,
colorectal, and pre-menopausal breast malignancies.
The circulating IGF-I concentrations were not related to
any lung cancer risk. Thus our results suggest that,
rather than IGF-I, IGF-IR expression and degradation
may play a role in lung cancer. IGF-IR is often
overexpressed in malignant tumors of tyroid, colon,
prostate, and in synovial carcinoma (Werner et al., 1989;
Werner, 1998; Belfiore et al., 1999; All-Ericsson et al.,
2002; Samani et al., 2004). The mechanisms behind such
cellular upregulation are not clearly understood. Other
authors have suggested that the degradation processes
may represent a crucial step in such development
(Larsson et al., 2005), and our studies may support this
hypothesis. Recently, the exposure of human cell lines,
MCF-7 and A549, to specific antibodies against IGF-IR,
was able to inhibit receptor signaling, cell cycle
progression, and promote degradation of the receptor.
Importantly, this approach increased the tumor sensi-
tivity to other therapeutic compounds such as vinor-
elbine (Goetsch et al., 2005). Moreover, it is becoming
apparent that endocytic routes taken by the receptors,
such as EGF receptor (Haglung and Dikic, 2005;
Sigismund et al., 2005), neutrophin receptors (Zhang
et al., 2000), and transforming growth factor (TGF)-b
receptor (Di Guglielmo et al., 2003), may influence their
signaling quality, strength, and duration, and concern-
ing to that, ubiquitination play an important role in
directing sub-cellular localization and intracellular
traffic of receptors (Haglund et al., 2003).
In conclusion, we show that IGF-IR b chain is
overexpressed in NSCLC tissue homogenates, this
might be related to changes in endocytosis and degrada-
tion events that are involved in IGF-IR downregulation.
IGF-IR is degraded via ubiquitin-proteasome pathway
in Npl cell lines and fresh tissue specimens from
NSCLC, while the lysosomal route is employed in non-
Npl lung tissue. Our evidences of the existence of a
divergent degradation route of IGF-IR in non-Npl and
Npl lung cells might also suggest that the receptor
signals might be different in the two cell types, and that
it could be an appropriate target for novel pharmacolo-
gical approaches to IGF-IR-positive cancers.
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